证券代码：300595 证券简称：欧普康视 公告编号：2025-035 欧普康视科技股份有限公司（以下简称"公司"）于 2024 年 12 月 24 日披 露了《关于持股 5%以上股东减持股份预披露公告》（公告编号：2024-102）， 持有公司股份 122,790,521 股的股东南京欧陶信息科技有限公司（以下简称"南 京欧陶"）计划在本公告披露之日起十五个交易日后的三个月内通过集中竞价交 易或大宗交易方式合计减持不超过公司股份总数 3%。其中，通过集中竞价交易 减持的股份总数不得超过公司总股本的 1%；通过大宗交易方式减持的股份总数 不得超过公司总股本的 2%。 公司于 2025 年 3 月 11 日披露了《关于持股 5%以上股东减持公司股份触及 1%整数倍的公告》（公告编号：2025-010），南京欧陶在 2025 年 3 月 7 日通过 大宗交易的方式合计减持公司股份 896 万股，占公司总股本的 1.00%。本次权益 变动后，南京欧陶的持股比例由 13.70%变动为 12.70%，变动触及 1%的整数倍。 公司于 2025 年 4 月 1 日披露了《关于持股 5%以上股东减持公司股份触及 1% 整数 ...

证券代码：300595 证券简称：欧普康视 公告编号：2025-034 欧普康视科技股份有限公司 关于持股5%以上股东部分股份补充质押的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 欧普康视科技股份有限公司（以下简称"公司"）于近日收到公司持股 5% 以上股东南京欧陶信息科技有限公司（以下简称"南京欧陶"）通知，获悉其将 持有公司股份 60 万股在山西证券股份有限公司办理了补充质押。现将具体情况 公告如下： 一、股东股份质押的基本情况 | | 是否为控 | | 占其 | 占公 | | 是否 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东 | 股股东或 | 本次质押数 | 所持 | 司总 | 是否 | 为补 | 质押 | 质押 | | 质押 | | 名称 | 第一大股 | 量（股） | 股份 | 股本 | 为限 | 充质 | 起始日 | 到期日 | 质权人 | 用途 | | | 东及其一 | | 比例 | 比例 | 售股 | 押 | | ...

证券代码：300595 证券简称：欧普康视 欧普康视科技股份有限公司 2025 年 4 月 17 日投资者关系活动记录表 编号：2025-002 投资者关系 活动类别 □特定对象调研 □分析师会议 □媒体采访 ☑业绩说明会 □新闻发布会 □路演活动 □现场参观 □在线会议 参与单位人 员情况 线上参与欧普康视 2024 年年度报告网上说明会的投资者 时 间 2025 年 4 月 17 日（星期四）下午 15:30-17:00 地 点 "约调研"微信小程序 上市公司参 会人员 创始人、董事长兼总经理 陶悦群博士 董事、副总经理兼董事会秘书 施贤梅女士 董事、财务总监 卫立治先生 独立董事 许立新先生 投资者关系 活动交流主 要内容介绍 本次 2024 年年度报告网上说明会主要问答如下： Q1：从 2024 年年报看，公司营业收入同比增长 4.40%，但归母净利 润却同比下降 14.16%，请问公司认为导致净利润下滑的最核心因素是什 么？在 2025 年，公司计划采取哪些具体措施来改善盈利状况，提升净利 润水平？ A：您好，您可参考年报中 P15"主要业绩驱动因素"中有详细的分析， 另外在 P48-51 有关于后 ...

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology industry, expecting the industry index to outperform the market index by over 10% in the next six months [2][29]. Core Insights - The SW pharmaceutical and biotechnology industry underperformed the CSI 300 index, declining by 5.20% from March 28 to April 10, 2025, which is approximately 0.18 percentage points lower than the index [14][29]. - Most sub-sectors within the industry recorded negative returns during the same period, with blood products and offline pharmacy sectors showing gains of 7.36% and 1.41%, respectively, while medical R&D outsourcing and in vitro diagnostics faced declines of 21.38% and 10.62% [15][29]. - Approximately 17% of stocks in the industry recorded positive returns, while around 83% experienced negative returns during the reporting period [16][19]. - The overall price-to-earnings (PE) ratio for the SW pharmaceutical and biotechnology industry is approximately 38.81 times, which is 3.38 times relative to the CSI 300, indicating a decline in industry valuation and positioning at a relatively low level compared to recent years [20][29]. Summary by Sections 1. Market Review - The SW pharmaceutical and biotechnology industry underperformed the CSI 300 index, with a decline of 5.20% from March 28 to April 10, 2025 [14]. - Most sub-sectors recorded negative returns, with blood products and offline pharmacies leading in gains [15]. - About 17% of stocks in the industry had positive returns, while 83% had negative returns [16]. 2. Industry News - The national Chinese medicine procurement alliance began centralized procurement and information maintenance for selected drugs starting April 9, 2025, involving 20 product groups and 95 products, with 174 drugs selected [26]. 3. Important Announcements from Listed Companies - Zai Lab received approval for clinical trials of its drug ZG005 for use in combination with chemotherapy for digestive tumors [27]. - Opcon Vision received a medical device registration certificate for its orthokeratology contact lenses [28]. 4. Industry Weekly Perspective - The report suggests focusing on investment opportunities in medical devices and innovative drugs, particularly those with import substitution potential [29]. - Recommended stocks include Mindray Medical, Yuyuan Pharmaceutical, and others across various segments such as medical aesthetics and innovative drugs [30].

Group 1 - The company, Opcon Vision (300595), has received a medical device registration certificate from the National Medical Products Administration for its new product, "Orthokeratology Rigid Gas Permeable Contact Lens" [1] - The product is designed for temporary correction of myopia for users with myopia degrees between -0.50D and -4.00D and astigmatism degrees within 1.50D [1] - The product is non-sterile and requires cleaning and disinfection before use, with a recommended replacement cycle of one year and a shelf life of five years [1]

证券代码：300595 证券简称：欧普康视 公告编号：2025-033 欧普康视科技股份有限公司 关于角膜塑形用硬性透气接触镜获得医疗器械注册证的公 告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 欧普康视科技股份有限公司（以下简称"公司"）于近日收到国家药品监督 管理局颁发的《中华人民共和国医疗器械注册证》（注册证编号：国械注准 20253160760），公司的"角膜塑形用硬性透气接触镜"新产品已完成注册并获 得第三类医疗器械注册证。现将具体信息公告如下： 一、注册产品基本情况 1、注册人名称：欧普康视科技股份有限公司 2、注册人住所：合肥市高新区望江西路 4899 号 3、生产地址：合肥市高新区望江西路 4899 号 4、产品名称：角膜塑形用硬性透气接触镜 9、注册证编号：国械注准 20253160760 10、审批部门：国家药品监督管理局 11、批准日期：2025 年 4 月 9 日 12、有效期：2025 年 4 月 9 日—2030 年 4 月 8 日 二、产品的审批流程 1、目前所处注册审批阶段：注册已完成。 2、后续所需审批流程：无，注册证有 ...

证券代码：300595 证券简称：欧普康视 公告编号：2025-032 欧普康视科技股份有限公司 关于持股5%以上股东部分股份解除质押的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 欧普康视科技股份有限公司（以下简称"公司"）于近日收到公司持股 5% 以上股东南京欧陶信息科技有限公司（以下简称"南京欧陶"）通知，获悉其将 前期质押给广发证券股份有限公司的 559.9079 万股解除质押。现将具体情况公 告如下： 一、股东股份解除质押的基本情况 | 股东 名称 | 是否为 控股股 东或第 一大股 东及其 | 本次解除质 押股份数量 （股） | 占其所 持股份 比例（%） | 占公司 总股本 比例（%） | 起始日 | 解除日期 | 质权人 | | --- | --- | --- | --- | --- | --- | --- | --- | | | 一致行 动人 | | | | | | | | | | 1,806,379 | 1.76 | 0.20 | 2023/7/6 | 2025/4/3 2025/4/3 | | | | 否 | 2,183,700 ...

Core Viewpoint - The eye health awareness among the Chinese population is increasing, leading to significant growth in the ophthalmic optical instrument industry, which is expected to reach a market size of approximately 4 billion yuan by 2024 [1][15]. Industry Overview - Ophthalmic optical instruments are essential for diagnosing and treating eye diseases, including devices like computer visual field analyzers, automatic refractors, corneal topographers, and fundus cameras [3][4]. - The industry has seen remarkable advancements in technology and product development, with domestic companies enhancing their R&D capabilities and launching high-quality products [1][15]. Market Growth - The market size of China's ophthalmic optical instrument industry has been continuously growing from 2017 to 2023, with projections indicating it will reach around 4 billion yuan in 2024 [1][15]. - The increasing prevalence of age-related eye diseases and lifestyle changes, such as prolonged use of electronic devices, are driving the demand for ophthalmic medical services [13][25]. Industry Chain - The upstream of the ophthalmic optical instrument industry includes suppliers of optical glass and plastic, which are crucial for manufacturing high-quality instruments [9][11]. - The midstream consists of various manufacturers of ophthalmic optical instruments, while the downstream includes hospitals, clinics, and optical shops where these instruments are utilized [9]. Competitive Landscape - The market concentration in the ophthalmic optical instrument industry is relatively high, with a few companies dominating specific product areas like fundus cameras and OCT devices [17][18]. - Key players in the industry include companies like 图拜医疗, 康捷医疗, and 新眼光, which are focusing on high-end product development [17][18]. Policy Environment - Recent policies have been introduced to promote the standardization and regulation of the medical device industry, providing favorable conditions for the growth of the ophthalmic optical instrument sector [4][6]. - The government aims to enhance the quality and safety of medical devices, ensuring a robust regulatory framework by 2035 [6]. Future Trends - The market is expected to further penetrate various healthcare institutions, with handheld devices likely to see widespread adoption in grassroots medical facilities [23]. - The integration of artificial intelligence and big data into ophthalmic optical instruments is becoming mainstream, leading to the development of smart devices that enhance diagnostic capabilities [24][25].

证券代码：300595 证券简称：欧普康视 公告编号：2025-031 欧普康视科技股份有限公司 关于持股5%以上股东部分股份补充质押的公告 1、股份质押基本情况 注：本公告中所涉数据的尾数差异或不符系四舍五入所致。 2、股份累计被质押的情况 截至本公告披露日，南京欧陶所持质押股份累计情况如下： | | | | | | | | 已质押股份 | | 未质押股份 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | 占其 | 占公 | 情况 | | 情况 | | | | | 持股 | 本次质押前 | 本次质押后 | 所持 | 司总 | 已质押 | 占已 | 未质押 | 占未 | | 股东 | 持股数 | 比例 | 质押股份数 | 质押股份数 | 股份 | 股本 | 股份限 | 质押 | 股份限 | 质押 | | 名称 | 量（股） | | | | | | 售和冻 | | | | | | | （%） | 量（股） | 量（股） | 比例 | 比例 | | 股份 | 售和冻 | 股份 | | | | | ...

证券研究报告·公司点评报告·医疗器械 欧普康视（300595） 2024 年年报点评：业绩短期承压，期待巩膜 镜贡献增量 增持（维持） [Table_Tag] [Table_Summary] 投资要点 2025 年 04 月 02 日 证券分析师 朱国广 | [Table_EPS] 盈利预测与估值 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万元） | 1737 | 1814 | 2060 | 2366 | 2738 | | 同比（%） | 13.89 | 4.40 | 13.59 | 14.86 | 15.70 | | 归母净利润（百万元） | 666.60 | 572.23 | 645.98 | 694.23 | 787.54 | | 同比（%） | 6.85 | (14.16) | 12.89 | 7.47 | 13.44 | | EPS-最新摊薄（元/股） | 0.74 | 0.64 | 0.72 | 0.77 | 0.88 | | P/E（现价&最新摊薄） | 21. ...